TAP2 and non-small cell lung carcinoma: As shown in the supplementary Fig. S8A, only 13 (1.5%) of 875 individual NSCLC cases contained deleterious mutations of the TAP2 gene that could explain the protein downregulation, supporting a non-genomic mechanism of TAP2 silencing.